Rubicon Research Limited — Q1FY27 earnings call summary

Filed 14 August 2026 · Company audio recording

FY27 EBITDA margin guidance revised upward to ~23% from earlier 20%, despite growth investments and cost pressures.
Multiple Indian sites aligned with portfolio needs, enabling risk diversification and capacity for niche and high-potency products.
Incremental costs related to ESOPs, Arena growth investments, and pre-revenue expenses for new facilities may pressure margins short term.
R&D spend on track for ₹500 crores over 9 quarters ending Q1 FY28, maintaining 10.9% of revenue; productivity improving (5.5x revenue to R&D ratio).
Gross margin improved sequentially by 140bps to 67.7% despite higher input and credit costs.
Operating EBITDA margin rose to 24.2% in Q1, aided by pricing power and operational efficiencies despite inflation and employee appraisal costs.
Pitampur facility FDA-approved post-inspection; commercial ramp-up expected from Q1 CY27 with significant expansion headroom on 30-acre site.
Temporary cash flow impact in Q1 due to GST refund delays, expected to normalize in Q2.